Grenoble, July 8th, 2021 – LXRepair, a biotechnology start-up specializing in personalized medicine testing, today announces the granting of €750,000 in funding under the BPI France DeepTech program. This program supports advanced and highly differentiating biotechnology projects with significant commercial potential.
This is the case of LXRepair: predicting serious late side effects is the “Holy Grail” of radiotherapists. Caused by DNA repair defects, they affect 5 to 30% of patients and cost around 600 million euros per year in Europe and the United States for breast and prostate cancers alone.
Sylvie Sauvaigo: +33. 220.127.116.11.95. email@example.com
Stéphane Altaba : +18.104.22.168.20.03. firstname.lastname@example.org
Media Relations: Jean-Baptiste Mounier: +22.214.171.124.42.91. email@example.com